GABBR2
Gamma-aminobutyric acid type B receptor subunit 2
As of the edition of 20 October 2026, GABBR2 (gamma-aminobutyric acid type B receptor subunit 2, UniProt O75899) has 6 drugs tested at it and 21 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O75899
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 26
- Disease areas
- Nervous system; Mental health; Chemically induced; Bones, joints and muscles; Digestive system; Immune system; Inherited and neonatal; Injuries
- Registered trials of its drugs
- 152
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Baclofen | Marketed | Phase 4 | none listed |
| Oxybate | Marketed | Phase 4 | Ends 2028 |
| Arbaclofen | Stopped | Phase 3 | none listed |
| Lesogaberan | Went quiet | Phase 2 | none listed |
| Arbaclofen placarbil | Went quiet | Phase 2 | none listed |
| SGS-742 | Went quiet | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 20 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
The other 20 companies at GABBR2
In the product21 companies in all; 20 are not named here, and no score is.
See the 21 companies at GABBR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.